Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo
- 31 January 2009
- journal article
- Published by Elsevier BV in Atherosclerosis
- Vol. 202 (1), 76-83
- https://doi.org/10.1016/j.atherosclerosis.2008.04.010
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Increased Toll-Like Receptor (TLR) 2 and TLR4 Expression in Monocytes from Patients with Type 1 Diabetes: Further Evidence of a Proinflammatory StateJournal of Clinical Endocrinology & Metabolism, 2008
- Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipidsAtherosclerosis, 2008
- High glucose induces IL-1β expression in human monocytes: mechanistic insightsAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Cooperation of Toll-like receptor signals in innate immune defenceNature Reviews Immunology, 2007
- Toll-like receptors and innate immunityJournal of Molecular Medicine, 2006
- Anti-inflammatory and metabolic effects of candesartan in hypertensive patientsInternational Journal of Cardiology, 2006
- TLR signalingCell Death & Differentiation, 2006
- Central role of the AT1-receptor in atherosclerosisJournal of Human Hypertension, 2002
- Tissue Angiotensin and Pathobiology of Vascular DiseaseHypertension, 2001
- Modulation of arterial thrombosis by angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockadeThe American Journal of Cardiology, 1998